AZ’s Evusheld Receives World-First Approval As COVID-19 Treatment, In Japan
Contrast With UK Decisions
Japan has approved Evusheld for both the prevention of infection in people who have not been exposed to the virus and, for the first time globally, as a treatment. The country's government will purchase 300,000 units from AZ amid global supplies that have been limited due to the surging need for the drug.
You may also be interested in...
News that the UK government will not procur any doses of AstraZeneca’s Evusheld for the prevention of COVID-19 infections in immunocompromised people has been greeted with dismay and the move will hurt the combo's already-limited sales growth.
Shionogi is hoping to demonstrate the efficacy of its oral COVID-19 candidate Xocova through an appropriate primary endpoint in its Phase III trial, while the Japanese firm is also eyeing global expansion for the drug should a world-first domestic approval be granted.
AstraZeneca has presented more promising data from the PROVENT trial of its antibody combination therapy Evusheld which shows high levels of protection from COVID-19 for at least six months.